# A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)

> **NCT02614131** · PHASE1 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 50 (actual)

## Conditions studied

- Healthy
- Alzheimer's Disease
- Mild Cognitive Impairment

## Interventions

- **DRUG:** LY2599666
- **DRUG:** Solanezumab
- **DRUG:** Placebo SC
- **DRUG:** Placebo IV

## Key facts

- **NCT ID:** NCT02614131
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 50 (ACTUAL)
- **Why stopped:** New data suggests that insufficient target engagement would be achieved for efficacy.
- **Last updated:** 2020-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02614131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02614131, "A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02614131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*